Published online: 17 February 2018
Springer Science+Business Media, LLC, part of Springer Nature 2018
With this Issue, I am beginning a new challenge and commit-
ment as Editor–in-Chief of the Glycoconjugate Journal (GJ).
Following in the footsteps of Hans Vliegenthart will not be
easy, but I will do my utmost to maintain the high quality
standards achieved and maintained during his Editorship. I
would like to take this opportunity to thank Hans for his tire-
less dedication to the Journal.
As you are all probably aware, the Glycoconjugate
Journal, the Official Journal of the International
Glycoconjugate Organization (IGO), was founded in 1984
by M.A. Chester, who together with the IGO Board organized
an outstanding first issue comprising manuscripts from lead-
ing glyco-groups. I will be working hard to continue to devel-
op this presence of quality manuscripts from top research
groups while also making the GJ an attractive place to publish
for the next generation of scientists.
In recent years, the Impact Factor of GJ has fluctuated
around the 2.0 mark. Taking into account the rich history of
the Journal and together with your support, I will be working
hard to improve on this metric. GJ is pleased to publish edi-
torials, letters, commentaries, original articles, reviews and
announcements in any field of glycoconjugate science.
In order to achieve our aims, all our Editors will be acting
as Handling Editors, responsible for carrying out the peer-
review process and for taking the final decision. Authors will
be able to select a Handling Editor based on their expertise and
we are confident that this will help toward a timely and effi-
cient peer review process.
GJ, of course, welcomes your suggestions for journal de-
velopments and initiatives, and of equal importance, we wel-
come your submissions to the Journal.
We are confident that the Glycoconjugate Journal will suc-
ceed in becoming a stronger and better recognized high qual-
ity journal for the publication of your research.
Professor of Biochemistry
Department of Medical Biotechnology and Translational Medicine
University of Milan, Italy
* Sandro Sonnino
Department of Medical Biotechnology and Translational Medicine,
University of Milan, Milan, Italy
Glycoconjugate Journal (2018) 35:1